Search

Your search keyword '"Juliusson, Gunnar"' showing total 491 results
Start Over Author "Juliusson, Gunnar" Language english
491 results on '"Juliusson, Gunnar"'

1. Hairy cell leukemia variant and WHO classification correspondence Re: 5th edition WHO classification haematolymphoid tumors: lymphoid neoplasms

Author

Grever, Michael, Andritsos, Leslie, Anghelina, Mirela, Arons, Evgeny, Banerji, Versha, Barrientos, Jacqueline, Bhat, Seema A., Blachly, James, Broccoli, Alessandro, Call, Timothy, Dearden, Claire, Dietrich, Sascha, Else, Monica, Epperla, Narendranath, Fagarasanu, Andrei, Falini, Brunangelo, Forconi, Francesco, Gozzetti, Alessandro, Hampel, Paul, Hermel, David J., Iyengar, Sunil, Johnston, James B., Juliusson, Gunnar, Kreitman, Robert J., Lauria, Francesco, Lozanski, Gerard, Oakes, Christopher C., Parikh, Sameer A., Park, Jae, Quest, Graeme, Rai, Kanti, Ravandi, Farhad, Robak, Tadeusz, Rogers, Kerry A., Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine S., Tiacci, Enrico, Troussard, Xavier, Wörmann, Bernhard, Zent, Clive S., Zenz, Thorsten, and Zinzani, Pier Luigi

Published
2024
Full Text
View/download PDF

3. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Author

Fürstenau, Moritz, Kater, Arnon P, Robrecht, Sandra, von Tresckow, Julia, Zhang, Can, Gregor, Michael, Thornton, Patrick, Staber, Philipp B, Tadmor, Tamar, Lindström, Vesa, Juliusson, Gunnar, Janssens, Ann, Levin, Mark-David, da Cunha-Bang, Caspar, Schneider, Christof, Goldschmidt, Neta, Vandenberghe, Elisabeth, Rossi, Davide, Benz, Rudolf, Nösslinger, Thomas, Heintel, Daniel, Poulsen, Christian B, Christiansen, Ilse, Frederiksen, Henrik, Enggaard, Lisbeth, Posthuma, Eduardus F M, Issa, Djamila E, Visser, Hein P J, Bellido, Mar, Kutsch, Nadine, Dürig, Jan, Stehle, Alexander, Vöhringer, Matthias, Böttcher, Sebastian, Schulte, Clemens, Simon, Florian, Fink, Anna-Maria, Fischer, Kirsten, Holmes, Emily E, Kreuzer, Karl-Anton, Ritgen, Matthias, Brüggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Hallek, Michael, Niemann, Carsten U, and Eichhorst, Barbara

Published
2024
Full Text
View/download PDF

4. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Author

Fürstenau, Moritz, Thus, Yvonne J., Robrecht, Sandra, Mellink, Clemens H. M., van der Kevie-Kersemaekers, Anne-Marie, Dubois, Julie, von Tresckow, Julia, Patz, Michaela, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian Bjoern, Illmer, Thomas, Schöttker, Björn, Janssens, Ann, Christiansen, Ilse, Nösslinger, Thomas, Baumann, Michael, Hebart, Holger, Gaska, Tobias, Regelink, Josien C., Dompeling, Ellen C., Lindström, Vesa, Juliusson, Gunnar, Widmer, Anouk, Goede, Jeroen, Goldschmidt, Neta, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Ritgen, Matthias, Brüggemann, Monika, Tausch, Eugen, Spaargaren, Marcel, Eldering, Eric, Stilgenbauer, Stephan, Niemann, Carsten U., Hallek, Michael, Eichhorst, Barbara, Kreuzer, Karl-Anton, and Kater, Arnon P.

Published
2023
Full Text
View/download PDF

6. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

Author

Ravandi, Farhad, Kreitman, Robert J., Tiacci, Enrico, Andritsos, Leslie, Banerji, Versha, Barrientos, Jacqueline C., Bhat, Seema A., Blachly, James S., Broccoli, Alessandro, Call, Timothy, Chihara, Dai, Dearden, Claire, Demeter, Judit, Dietrich, Sasha, Else, Monica, Epperla, Narendranath, Falini, Brunangelo, Forconi, Francesco, Gladstone, Douglas E., Gozzetti, Alessandro, Iyengar, Sunil, Johnston, James B., Jorgensen, Jeffrey, Juliusson, Gunnar, Lauria, Francesco, Lozanski, Gerard, Parikh, Sameer A., Park, Jae H., Polliack, Aaron, Quest, Graeme, Robak, Tadeusz, Rogers, Kerry A., Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine S., Thompson, Philip A., Troussard, Xavier, Zent, Clive S., Zenz, Thorsten, Zinzani, Pier Luigi, Wörmann, Bernhard, Rai, Kanti, and Grever, Michael

Published
2022
Full Text
View/download PDF

7. Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data.

Author

Abé, Christoph, Keto, Jaana, Lilja, Mathias, Konradsen, Mie, Mesterton, Johan, Höglund, Martin, Lazarevic, Vladimir, Lehmann, Sören, and Juliusson, Gunnar

Subjects
HEMATOPOIETIC stem cell transplantation, ACUTE myeloid leukemia, OLDER patients, PROPENSITY score matching, OVERALL survival
Abstract

Since 1980's, the established/standard treatment of acute myeloid leukemia (AML) is cytarabine infusion with anthracycline (7 + 3 regimen). We compared the 7 + 3 regimen in older secondary/high-risk AML patients from a clinical trial with a matched population from the Swedish AML Registry treated with an increased cytarabine dose in induction and consolidation as recommended in the Swedish National Guidelines since 2005. After successful propensity score matching, 104 patients per group were included. The primary outcome was overall survival (OS), and standard dosed patients had a median OS of 6.4 versus 10.7 months with increased dose intensity (hazard ratio: 0.69, p = 0.012), with 5-year OS of 8.7% and 18.1%, and remission rates of 36% and 60%, respectively (p < 0.001). Median OS after allogeneic hematopoietic cell transplantation (in 27.9% per group) was 10.4 and 20.7 months, respectively. We conclude that the more intensive cytarabine schedule seems to provide improved outcomes inthe investigated AML patient group. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Complex Relationships between Diagnostics and Survival in Chronic Lymphocytic Leukemia in Denmark, Finland, Norway, and Sweden.

Author

Hemminki, Kari, Zitricky, Frantisek, Försti, Asta, Tapaninen, Tuija, Hemminki, Akseli, Juliusson, Gunnar, and Niemann, Carsten Utoft

Subjects
CHRONIC lymphocytic leukemia diagnosis, CHRONIC lymphocytic leukemia, MORTALITY, RESEARCH funding, SEX distribution, AGE distribution, DESCRIPTIVE statistics, CHRONIC diseases
Abstract

Simple Summary: Chronic lymphocytic leukemia (CLL) is a common leukemia characterized by an accumulation of lymphocytes in the blood and lymphoid organs. Disease presentation is highly variable as many patients do not initially require any treatment, and a watch and wait strategy remains the standard of care for up to 50% of patients. However, for those with a progressive disease, chemotherapy is the standard treatment and has improved over the years, increasing the survival of patients. We analyze here age-specific relative survival trends in CLL through 50 years up to 2020s in Denmark, Finland, Norway, and Sweden using the NORDCAN database. The large age-specific survival differences in 1972–76 almost disappeared by 2017–21. While 5-year survival in younger patients exceeded 90%, for those diagnosed at age 80–89-years, survival improved later, reaching 90% in Denmark and less in the other countries. Survival in Denmark is probably among the best in the world, which could be achieved by boosting survival even among the oldest patients. Most Nordic survival rates were better than those in the USA. Background: Chronic lymphocytic leukemia (CLL) is a common hematological malignancy with highly variable clinical presentation. Many patients never require any treatment but for the others, chemotherapy, immunochemotherapy, and newer targeted therapies have changed the treatment landscape. Diagnostic age influences the applied treatment, and we thus wanted to analyze age-specific survival trends through 50 years up to 2020s. Methods: We used 1- and 5-year relative survival from the NORDCAN database, with data from Denmark (DK), Finland (FI), Norway (NO), and Sweden (SE). Because of the variable presentation of CLL, we also considered incidence and mortality trends. For comparison, US SEER data were used. Results: The large age-specific survival differences in 1972–76 almost disappeared by 2017–21. While 5-year survival in younger patients exceeded 90%, for those diagnosed at age 80–89 years, survival reached 90% in DK and SE women, 80% in NO and SE men, but only 50% in FI. DK 5-year overall survival for men was 92.4%, and for women, it was 96.3%. These survival figures were higher than age-group-specific US survival data. Conclusions: The DK data are probably global top figures for national survival which could be achieved by boosting survival even among the oldest patients. The qualification to these figures and international comparisons is that survival needs to be considered in terms of incidence, which is high in DK and NO. Low survival of the FI 80–89-year-old patients, even in the first year after diagnosis, may suggest delayed diagnosis, which should call for a closer national scrutiny. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Author

Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J., Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W., Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J.F.M., Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W.J., Bargetzi, Mario, Klein, Saskia K., Gadisseur, Alain, Westerweel, Peter E., Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A., Hoogendoorn, Mels, Legdeur, Marie-Cecile J.C., Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T., Janssen, Jeroen J.W.M., Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J.M., van Elssen, Catharina H.M.J., Manz, Markus G., Floisand, Yngvar, and Ossenkoppele, Gert J.

Published
2021
Full Text
View/download PDF

10. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

Author

Grever, Michael, Andritsos, Leslie, Banerji, Versha, Barrientos, Jacqueline C., Bhat, Seema, Blachly, James S., Call, Timothy, Cross, Matthew, Dearden, Claire, Demeter, Judit, Dietrich, Sasha, Falini, Brunangelo, Forconi, Francesco, Gladstone, Douglas E., Gozzetti, Alessandro, Iyengar, Sunil, Johnston, James B., Juliusson, Gunnar, Kraut, Eric, Kreitman, Robert J., Lauria, Francesco, Lozanski, Gerard, Parikh, Sameer A., Park, Jae, Polliack, Aaron, Ravandi, Farhad, Robak, Tadeusz, Rogers, Kerry A., Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine S., Tiacci, Enrico, Troussard, Xavier, Zent, Clive, Zenz, Thorsten, Zinzani, Pier Luigi, and Wörmann, Bernhard

Published
2021
Full Text
View/download PDF

11. Precision Diagnostics in Myeloid Malignancies: Development and Validation of a National Capture‐Based Gene Panel.

Author

Orsmark‐Pietras, Christina, Lyander, Anna, Ladenvall, Claes, Hallström, Björn, Staffas, Anna, Awier, Hero, Krstic, Aleksandra, Baliakas, Panagiotis, Barbany, Gisela, Håkansson, Cecilia Brunhoff, Gellerbring, Anna, Hagström, Anna, Hellström‐Lindberg, Eva, Juliusson, Gunnar, Lazarevic, Vladimir, Munters, Arielle, Pandzic, Tatjana, Wadelius, Mia, Ås, Joel, and Fogelstrand, Linda

Published
2024
Full Text
View/download PDF

12. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial

Author

Ngai, Lok Lam, Hanekamp, Diana, Janssen, Fleur, Carbaat-Ham, Jannemieke, Hofland, Maaike A M, Fayed, Mona M H E, Kelder, Angèle, Oudshoorn-van Marsbergen, Laura, Scholten, Willemijn J, Snel, Alexander N, Bachas, Costa, Tettero, Jesse M, Breems, Dimitri A, Fischer, Thomas, Gjertsen, Bjorn T, Griskevicius, Laimonas, Juliusson, Gunnar, van de Loosdrecht, Arjan A, Maertens, Johan A, Manz, Markus G, Pabst, Thomas, Passweg, Jakob R, Porkka, Kimmo, Valk, Peter J M, Gradowska, Patrycja, Löwenberg, Bob, de Leeuw, David C, Janssen, Jeroen J W M, Ossenkoppele, Gert J, Cloos, Jacqueline, Hematology laboratory, VU University medical center, Hematology, AII - Cancer immunology, AII - Inflammatory diseases, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, and CCA - Cancer Treatment and quality of life

Subjects
All institutes and research themes of the Radboud University Medical Center, Immunology, Cell Biology, Hematology, 610 Medicine & health, Biochemistry, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract

Item does not contain fulltext

Published
2023

15. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia

Author

Anguille, Sébastien, Van de Velde, Ann L., Smits, Evelien L., Van Tendeloo, Viggo F., Juliusson, Gunnar, Cools, Nathalie, Nijs, Griet, Stein, Barbara, Lion, Eva, Van Driessche, Ann, Vandenbosch, Irma, Verlinden, Anke, Gadisseur, Alain P., Schroyens, Wilfried A., Muylle, Ludo, Vermeulen, Katrien, Maes, Marie-Berthe, Deiteren, Kathleen, Malfait, Ronald, Gostick, Emma, Lammens, Martin, Couttenye, Marie M., Jorens, Philippe, Goossens, Herman, Price, David A., Ladell, Kristin, Oka, Yoshihiro, Fujiki, Fumihiro, Oji, Yusuke, Sugiyama, Haruo, and Berneman, Zwi N.

Published
2017
Full Text
View/download PDF

16. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Author

Grever, Michael R., Abdel-Wahab, Omar, Andritsos, Leslie A., Banerji, Versha, Barrientos, Jacqueline, Blachly, James S., Call, Timothy G., Catovsky, Daniel, Dearden, Claire, Demeter, Judit, Else, Monica, Forconi, Francesco, Gozzetti, Alessandro, Ho, Anthony D., Johnston, James B., Jones, Jeffrey, Juliusson, Gunnar, Kraut, Eric, Kreitman, Robert J., Larratt, Loree, Lauria, Francesco, Lozanski, Gerard, Montserrat, Emili, Parikh, Sameer A., Park, Jae H., Polliack, Aaron, Quest, Graeme R., Rai, Kanti R., Ravandi, Farhad, Robak, Tadeusz, Saven, Alan, Seymour, John F., Tadmor, Tamar, Tallman, Martin S., Tam, Constantine, Tiacci, Enrico, Troussard, Xavier, Zent, Clive S., Zenz, Thorsten, Zinzani, Pier Luigi, and Falini, Brunangelo

Published
2017
Full Text
View/download PDF

17. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations

Author

Ljungström, Viktor, Cortese, Diego, Young, Emma, Pandzic, Tatjana, Mansouri, Larry, Plevova, Karla, Ntoufa, Stavroula, Baliakas, Panagiotis, Clifford, Ruth, Sutton, Lesley-Ann, Blakemore, Stuart J., Stavroyianni, Niki, Agathangelidis, Andreas, Rossi, Davide, Höglund, Martin, Kotaskova, Jana, Juliusson, Gunnar, Belessi, Chrysoula, Chiorazzi, Nicholas, Panagiotidis, Panagiotis, Langerak, Anton W., Smedby, Karin E., Oscier, David, Gaidano, Gianluca, Schuh, Anna, Davi, Frederic, Pott, Christiane, Strefford, Jonathan C., Trentin, Livio, Pospisilova, Sarka, Ghia, Paolo, Stamatopoulos, Kostas, Sjöblom, Tobias, and Rosenquist, Richard

Published
2016
Full Text
View/download PDF

18. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival

Author

Tettero, Jesse M, Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A, Fischer, Thomas, Gjertsen, Bjorn T, Gradowska, Patrycja, Griskevicius, Laimonas, Janssen, Jeroen J W M, Juliusson, Gunnar, Maertens, Johan, Manz, Markus G, Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Valk, Peter J M, Löwenberg, Bob, Ossenkoppele, Gert J, and Cloos, Jacqueline

Subjects
610 Medicine & health, Hematology
Abstract

Not available.

Published
2023

19. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology

Author

Went, Molly, Sud, Amit, Speedy, Helen, Sunter, Nicola J., Försti, Asta, Law, Philip J., Johnson, David C., Mirabella, Fabio, Holroyd, Amy, Li, Ni, Orlando, Giulia, Weinhold, Niels, van Duin, Mark, Chen, Bowang, Mitchell, Jonathan S., Mansouri, Larry, Juliusson, Gunnar, Smedby, Karin E, Jayne, Sandrine, Majid, Aneela, Dearden, Claire, Allsup, David J., Bailey, James R., Pratt, Guy, Pepper, Chris, Fegan, Chris, Rosenquist, Richard, Kuiper, Rowan, Stephens, Owen W., Bertsch, Uta, Broderick, Peter, Einsele, Hermann, Gregory, Walter M., Hillengass, Jens, Hoffmann, Per, Jackson, Graham H., Jöckel, Karl-Heinz, Nickel, Jolanta, Nöthen, Markus M., da Silva Filho, Miguel Inacio, Thomsen, Hauke, Walker, Brian A., Broyl, Annemiek, Davies, Faith E., Hansson, Markus, Goldschmidt, Hartmut, Dyer, Martin J. S., Kaiser, Martin, Sonneveld, Pieter, Morgan, Gareth J., Hemminki, Kari, Nilsson, Björn, Catovsky, Daniel, Allan, James M., and Houlston, Richard S.

Published
2019
Full Text
View/download PDF

20. Characterization of therapy-related acute myeloid leukemia : increasing incidence and prognostic implications

Author

Nilsson, Christer, Linde, Fredrika, Hulegardh, Erik, Garelius, Hege, Lazarevic, Vladimir, Antunovic, Petar, Cammenga, Jorg, Deneberg, Stefan, Eriksson, Anna, Jadersten, Martin, Bjorkvall, Cecilia Kampe, Mollgard, Lars, Wennstrom, Lovisa, Olander, Emma, Höglund, Martin, Juliusson, Gunnar, and Lehmann, Sören

Subjects
Cancer och onkologi, Cancer and Oncology, Hematology, Hematologi
Abstract

Studies of therapy-related AML (t-AML) are usually performed in selected cohorts and reliable incidence rates are lacking. In this study, we characterized, defined the incidence over time and studied prognostic implications in all t-AML patients diagnosed in Sweden between 1997 and 2015. Data were retrieved from nationwide population-based registries. In total, 6,779 AML patients were included in the study, of whom 686 (10%) had t-AML. The median age for t-AML was 71 years and 392 (57%) patients were females. During the study period, the incidence of t-AML almost doubled with a yearly increase in t-AML of 4.5% (95% confidence interval: 2.8%-6.2%), which contributed significantly to the general increase in AML incidence over the study period. t-AML solidly constituted over 10% of all AML cases during the later period of the study. Primary diagnoses with the largest increase in incidence and decrease in mortality rate during the study period (i.e., breast and prostate cancer) contributed significantly to the increased incidence of t-AML. In multivariable analysis, t-AML was associated with poorer outcome in cytogenetically intermediate-and adverse-risk cases but t-AML had no significant impact on outcome in favorable-risk AML, including core binding leukemias, acute promyelocytic leukemia and AML with mutated NPM1 without FLT3-ITD. We conclude that there is a strong increase in incidence in t-AML over time and that t-AML constitutes a successively larger proportion of the AML cases. Furthermore, we conclude that t-AML confers a poor prognosis in cytogenetically intermediate-and adverse-risk, but not in favorable-risk AML.

Published
2023

21. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Author

Furstenau, Moritz, Thus, Yvonne, Robrecht, Sandra, Mellink, Clemens, der Kevie-Kersemaekers, Anne-Marie, Dubois, Julie M. N., Von Tresckow, Julia, Patz, Michaela, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian Bjørn, Illmer, Thomas, Schöttker, Björn, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Noesslinger, Thomas, Regelink, Josien, Dompeling, Ellen C, Lindström, Vesa, Juliusson, Gunnar, Widmer, Anouk, Goede, Jeroen Simon, Goldschmidt, Neta, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Ritgen, Matthias, Brüggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Eldering, Eric, Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara, Kreuzer, Karl-Anton, and Kater, Arnon P.

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

23. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study

Author

Baliakas, Panagiotis, Hadzidimitriou, Anastasia, Sutton, Lesley-Ann, Minga, Eva, Agathangelidis, Andreas, Nichelatti, Michele, Tsanousa, Athina, Scarfò, Lydia, Davis, Zadie, Yan, Xiao-Jie, Shanafelt, Tait, Plevova, Karla, Sandberg, Yorick, Vojdeman, Fie Juhl, Boudjogra, Myriam, Tzenou, Tatiana, Chatzouli, Maria, Chu, Charles C, Veronese, Silvio, Gardiner, Anne, Mansouri, Larry, Smedby, Karin E, Pedersen, Lone Bredo, van Lom, Kirsten, Giudicelli, Véronique, Francova, Hana Skuhrova, Nguyen-Khac, Florence, Panagiotidis, Panagiotis, Juliusson, Gunnar, Angelis, Lefteris, Anagnostopoulos, Achilles, Lefranc, Marie-Paule, Facco, Monica, Trentin, Livio, Catherwood, Mark, Montillo, Marco, Geisler, Christian H, Langerak, Anton W, Pospisilova, Sarka, Chiorazzi, Nicholas, Oscier, David, Jelinek, Diane F, Darzentas, Nikos, Belessi, Chrysoula, Davi, Frederic, Rosenquist, Richard, Ghia, Paolo, and Stamatopoulos, Kostas

Published
2014
Full Text
View/download PDF

24. Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Author

Ngai, Lok Lam, Hanekamp, Diana, Janssen, Fleur, Carbaat-Ham, Jannemieke, Hofland, Maaike A.M., Fayed, Mona M.H.E, Kelder, Angèle, Oudshoorn-van Marsbergen, Laura, Scholten, Willemijn J., Snel, Alexander N., Bachas, Costa, Tettero, Jesse M., Breems, Dimitri A., Fischer, Thomas, Gjertsen, Bjørn Tore, Griškevičius, Laimonas, Juliusson, Gunnar, Maertens, Johan A., Manz, Markus G, Pabst, Thomas, Passweg, Jakob R., Porkka, Kimmo, Gradowska, Patrycja, Lowenberg, Bob, de Leeuw, David C., Janssen, Jeroen J.W.M., Ossenkoppele, Gert J., and Cloos, Jacqueline

Published
2022
Full Text
View/download PDF

25. Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching

Author

Tettero, Jesse M., Ngai, Lok Lam, Bachas, Costa, Breems, Dimitri A., Fischer, Thomas, Gjertsen, Bjørn Tore, Gradowska, Patrycja, Griskevicius, Laimonas, Janssen, Jeroen J.W.M., Juliusson, Gunnar, Maertens, Johan A., Manz, Markus G, Pabst, Thomas, Passweg, Jakob, Porkka, Kimmo, Valk, Peter JM, Lowenberg, Bob, Ossenkoppele, Gert J., and Cloos, Jacqueline

Published
2022
Full Text
View/download PDF

28. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

Author

Agathangelidis, Andreas, Darzentas, Nikos, Hadzidimitriou, Anastasia, Brochet, Xavier, Murray, Fiona, Yan, Xiao-Jie, Davis, Zadie, van Gastel-Mol, Ellen J., Tresoldi, Cristina, Chu, Charles C., Cahill, Nicola, Giudicelli, Veronique, Tichy, Boris, Pedersen, Lone Bredo, Foroni, Letizia, Bonello, Lisa, Janus, Agnieszka, Smedby, Karin, Anagnostopoulos, Achilles, Merle-Beral, Helene, Laoutaris, Nikolaos, Juliusson, Gunnar, di Celle, Paola Francia, Pospisilova, Sarka, Jurlander, Jesper, Geisler, Christian, Tsaftaris, Athanasios, Lefranc, Marie-Paule, Langerak, Anton W., Oscier, David Graham, Chiorazzi, Nicholas, Belessi, Chrysoula, Davi, Frederic, Rosenquist, Richard, Ghia, Paolo, and Stamatopoulos, Kostas

Published
2012
Full Text
View/download PDF

30. Combinatorial molecule screening identified a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells

Author

Hultmark, Simon, Baudet, Aurélie, Schmiderer, Ludwig, Prabhala, Pavan, Palma-Tortosa, Sara, Sandén, Carl, Fioretos, Thoas, Sasidharan, Rajkumar, Larsson, Christer, Lehmann, Sören, Juliusson, Gunnar, Ek, Fredrik, and Magnusson, Mattias

Subjects
Leukemia, Myeloid, Acute, fms-Like Tyrosine Kinase 3, hemic and lymphatic diseases, Cell Line, Tumor, Acetamides, Mutation, Humans, Antineoplastic Agents, Cell Differentiation, Azepines, Diterpenes, Article
Abstract

Combination treatment has proven effective for patients with acute promyelocytic leukemia, exemplifying the importance of therapy targeting multiple components of oncogenic regulation for a successful outcome. However, recent studies have shown that the mutational complexity of acute myeloid leukemia (AML) precludes the translation of molecular targeting into clinical success. Here, as a complement to genetic profiling, we used unbiased, combinatorial in vitro drug screening to identify pathways that drive AML and to develop personalized combinatorial treatments. First, we screened 513 natural compounds on primary AML cells and identified a novel diterpene (H4) that preferentially induced differentiation of FLT3 wild-type AML, while FLT3-ITD/mutations conferred resistance. The samples responding to H4, displayed increased expression of myeloid markers, a clear decrease in the nuclear-cytoplasmic ratio and the potential of re-activation of the monocytic transcriptional program reducing leukemia propagation in vivo. By combinatorial screening using H4 and molecules with defined targets, we demonstrated that H4 induces differentiation by the activation of the protein kinase C (PKC) signaling pathway, and in line with this, activates PKC phosphorylation and translocation of PKC to the cell membrane. Furthermore, the combinatorial screening identified a bromo- and extra-terminal domain (BET) inhibitor that could further improve H4-dependent leukemic differentiation in FLT3 wild-type monocytic AML. These findings illustrate the value of an unbiased, multiplex screening platform for developing combinatorial therapeutic approaches for AML.

Published
2020

31. A risk score based on real-world data to predict early death in acute promyelocytic leukemia

Author

Österroos, Albin, Maia, Tania, Eriksson, Anna, Jädersten, Martin, Lazarevic, Vladimir, Wennström, Lovisa, Antunovic, Petar, Cammenga, Jörg, Deneberg, Stefan, Lorenz, Fryderyk, Möllgård, Lars, Uggla, Bertil, Ölander, Emma, Aguiar, Eliana, Trigo, Fernanda, Höglund, Martin, Juliusson, Gunnar, and Lehmann, Sören

Subjects
Hematology, Hematologi
Abstract

With increasingly effective treatments, early death (ED) has become the predominant reason for therapeutic failure in patients with acute promyelocytic leukemia (APL). To better prevent ED, patients with high-risk of ED must be identified. Our aim was to develop a score that predicts the risk of ED in a real-life setting. We used APL patients in the population based Swedish AML Registry (n=301) and a Portuguese hospital-based registry (n=129) as training and validation cohorts, respectively. The cohorts were comparable with respect to age (median, 54 and 53 years) and ED rate (19.6% and 18.6%). The score was developed by logistic regression analyses, risk-per-quantile assessment and scoring based on ridge regression coefficients from multivariable penalized logistic regression analysis. White blood cell count, platelet count and age were selected by this approach as the most significant variables for predicting ED. The score identified low-, high-and very high-risk patients with ED risks of 4.8%, 20.2% and 50.9% respectively in the training cohort and with 6.7%, 25.0% and 36.0% as corresponding values for the validation cohort. The score identified an increased risk of ED already at sub-normal and normal white blood cell counts and, consequently, it was better at predicting ED risk than the Sanz score (AUROC 0.77 vs. 0.64). In summary, we here present an externally validated and population-based risk score to predict ED risk in a real-world setting, identifying patients with the most urgent need of aggressive ED prevention. The results also suggest that increased vigilance for ED is already necessary at sub-normal/normal white blood cell counts. Funding Agencies|Swedish Association of Local Authorities and Regions; Swedish Cancer Society; Region Skane; Regionalt Cancercentrum Syd

Published
2022

34. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

Author

Levis, Mark, Ravandi, Farhad, Wang, Eunice S., Baer, Maria R., Perl, Alexander, Coutre, Steven, Erba, Harry, Stuart, Robert K., Baccarani, Michele, Cripe, Larry D., Tallman, Martin S., Meloni, Giovanna, Godley, Lucy A., Langston, Amelia A., Amadori, Sergio, Lewis, Ian D., Nagler, Arnon, Stone, Richard, Yee, Karen, Advani, Anjali, Douer, Dan, Wiktor-Jedrzejczak, W., Juliusson, Gunnar, Litzow, Mark R., Petersdorf, Stephen, Sanz, Miguel, Kantarjian, Hagop M., Sato, Takashi, Tremmel, Lothar, Bensen-Kennedy, Debra M., Small, Donald, and Smith, B. Douglas

Published
2011
Full Text
View/download PDF

35. Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries

Author

Wennström, Lovisa, Edslev, Pernille Wendtland, Abrahamsson, Jonas, Nrgaard, Jan Maxwell, Flisand, Yngvar, Forestier, Erik, Gustafsson, Göran, Heldrup, Jesper, Hovi, Liisa, Jahnukainen, Kirsi, Jonsson, Olafur Gisli, Lausen, Birgitte, Palle, Josefine, Zeller, Bernward, Holmberg, Erik, Juliusson, Gunnar, Stockelberg, Dick, and Hasle, Henrik

Published
2016
Full Text
View/download PDF

36. Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial.

Author

Jädersten, Martin, Lilienthal, Ingrid, Tsesmetzis, Nikolaos, Lourda, Magda, Bengtzén, Sofia, Bohlin, Anna, Arnroth, Cornelia, Erkers, Tom, Seashore‐Ludlow, Brinton, Giraud, Géraldine, Barkhordar, Giti S., Tao, Sijia, Fogelstrand, Linda, Saft, Leonie, Östling, Päivi, Schinazi, Raymond F., Kim, Baek, Schaller, Torsten, Juliusson, Gunnar, and Deneberg, Stefan

Subjects
ACUTE myeloid leukemia, HYDROXYUREA, STEM cell transplantation, POLYMERASE chain reaction, DIAGNOSIS, FEBRILE neutropenia
Abstract

Background: Treatment of newly diagnosed acute myeloid leukaemia (AML) is based on combination chemotherapy with cytarabine (ara‐C) and anthracyclines. Five‐year overall survival is below 30%, which has partly been attributed to cytarabine resistance. Preclinical data suggest that the addition of hydroxyurea potentiates cytarabine efficacy by increasing ara‐C triphosphate (ara‐CTP) levels through targeted inhibition of SAMHD1. Objectives: In this phase 1 trial, we evaluated the feasibility, safety and efficacy of the addition of hydroxyurea to standard chemotherapy with cytarabine/daunorubicin in newly diagnosed AML patients. Methods: Nine patients were enrolled and received at least two courses of ara‐C (1 g/m2/2 h b.i.d. d1‐5, i.e., a total of 10 g/m2 per course), hydroxyurea (1–2 g d1‐5) and daunorubicin (60 mg/m2 d1‐3). The primary endpoint was safety; secondary endpoints were complete remission rate and measurable residual disease (MRD). Additionally, pharmacokinetic studies of ara‐CTP and exvivo drug sensitivity assays were performed. Results: The most common grade 3‐4 toxicity was febrile neutropenia (100%). No unexpected toxicities were observed. Pharmacokinetic analyses showed a significant increase in median ara‐CTP levels (1.5‐fold; p = 0.04) in patients receiving doses of 1 g hydroxyurea. Ex vivo, diagnostic leukaemic bone marrow blasts from study patients were significantly sensitised to ara‐C by a median factor of 2.1 (p = 0.0047). All nine patients (100%) achieved complete remission, and all eight (100%) with validated MRD measurements (flow cytometry or real‐time quantitative polymerase chain reaction [RT‐qPCR]) had an MRD level <0.1% after two cycles of chemotherapy. Treatment was well‐tolerated, and median time to neutrophil recovery >1.0 × 109/L and to platelet recovery >50 × 109/L after the start of cycle 1 was 19 days and 22 days, respectively. Six of nine patients underwent allogeneic haematopoietic stem‐cell transplantation (allo‐HSCT). With a median follow‐up of 18.0 (range 14.9–20.5) months, one patient with adverse risk not fit for HSCT experienced a relapse after 11.9 months but is now in second complete remission. Conclusion: Targeted inhibition of SAMHD1 by the addition of hydroxyurea to conventional AML therapy is safe and appears efficacious within the limitations of the small phase 1 patient cohort. These results need to be corroborated in a larger study. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

39. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

Author

Waage, Anders, Gimsing, Peter, Fayers, Peter, Abildgaard, Niels, Ahlberg, Lucia, Björkstrand, Bo, Carlson, Kristina, Dahl, Inger Marie, Forsberg, Karin, Gulbrandsen, Nina, Haukås, Einar, Hjertner, Øyvind, Hjorth, Martin, Karlsson, Torbjörn, Knudsen, Lene Meldgaard, Nielsen, Johan Lanng, Linder, Olle, Mellqvist, Ulf-Henrik, Nesthus, Ingerid, Rolke, Jürgen, Strandberg, Maria, Sørbø, Jon Hjalmar, Wisløff, Finn, Juliusson, Gunnar, and Turesson, Ingemar

Published
2010
Full Text
View/download PDF

40. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial

Author

Gimsing, Peter, Carlson, Kristina, Turesson, Ingemar, Fayers, Peter, Waage, Anders, Vangsted, Annette, Mylin, Anne, Gluud, Christian, Juliusson, Gunnar, Gregersen, Henrik, Hjorth-Hansen, Henrik, Nesthus, Ingerid, Dahl, Inger Marie S, Westin, Jan, Nielsen, Johan Lanng, Knudsen, Lene Meldgaard, Ahlberg, Lucia, Hjorth, Martin, Abildgaard, Niels, Andersen, Niels Frost, Linder, Olle, and Wisløff, Finn

Published
2010
Full Text
View/download PDF

42. First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Author

Fürstenau, Moritz, Ritgen, Matthias, Robrecht, Sandra, Von Tresckow, Julia, Zhang, Can, Schilhabel, Anke, Gregor, Michael, Thornton, Patrick, Staber, Philipp Bernhard, Tadmor, Tamar, Lindström, Vesa, Juliusson, Gunnar, Janssens, Ann, Levin, Mark-David, Da Cunha-Bang, Caspar, Schneider, Christof, Goldschmidt, Neta, Vandenberghe, Elisabeth, Rossi, Davide, Benz, Rudolf A., Heintel, Daniel, Poulsen, Christian Bjørn, Christiansen, Ilse, Frederiksen, Henrik, Enggaard, Lisbeth, Posthuma, Eduardus, Issa, Djamila, Visser, Hein, Bellido, Mar, Kutsch, Nadine, Dürig, Jan, Stehle, Alexander, Voehringer, Matthias C., Böttcher, Sebastian, Schulte, Clemens, Simon, Florian, Fink, Anna-Maria, Fischer, Kirsten, Holmes, Emily, Kreuzer, Karl-Anton, Brüggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Hallek, Michael, Kater, Arnon P., Niemann, Carsten Utoft, and Eichhorst, Barbara F.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results